Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson & Johnson; ClinicalTrials.gov number, NCT05083169.).
Authors
- Paul A. F. Geerts (ORCID: https://orcid.org/0000-0002-1737-7133)
- Juan Luis Reguera (ORCID: https://orcid.org/0009-0009-6408-1747)
- Roberto Mina (ORCID: https://orcid.org/0000-0002-8144-541X)
- Hamza Hashmi (ORCID: https://orcid.org/0000-0002-4129-5867)
- Luciano J. Costa (ORCID: https://orcid.org/0000-0001-5362-2469)
- Jin Lu (ORCID: https://orcid.org/0000-0002-0946-3357)
- Anne K. Mylin
- Gastón Caeiro
- Ingrid Maria Cecilia Rubin (ORCID: https://orcid.org/0000-0002-6158-2927)
- Surbhi Sidana (ORCID: https://orcid.org/0000-0003-3288-7614)
- Ajay K. Nooka (ORCID: https://orcid.org/0000-0003-4165-6869)
- María‐Victoria Mateos (ORCID: https://orcid.org/0000-0003-2390-1218)
- Alain Kentos (ORCID: https://orcid.org/0000-0003-1255-867X)
- Meletios Athanasios Dimopoulos (ORCID: https://orcid.org/0000-0001-8990-3254)
- Joaquín Martínez‐López (ORCID: https://orcid.org/0000-0001-7908-0063)
- Magnus Johansson (ORCID: https://orcid.org/0000-0001-8811-2629)
- Charlotte T. Hansen
- Donna Reece (ORCID: https://orcid.org/0009-0002-9686-4323)
- Rachel Kobos
- Elena van Leeuwen-Segarceanu
- Kristen Lantz
- Diego Vieyra
- Elena Zamagni (ORCID: https://orcid.org/0000-0003-1422-7305)
- Britta Besemer
- Raphael Teipel (ORCID: https://orcid.org/0000-0002-9985-6583)
- Mark Grey
- Nizar Jacques Bahlis (ORCID: https://orcid.org/0000-0001-7353-7034)
- Agata Tyczyńska (ORCID: https://orcid.org/0000-0002-2067-2715)
- Charlotte Pawlyn (ORCID: https://orcid.org/0000-0002-7190-0028)
- Markus Hansson (ORCID: https://orcid.org/0000-0002-7715-4548)
- Ting Niu (ORCID: https://orcid.org/0000-0003-1580-1014)
- Lijuan Kang (ORCID: https://orcid.org/0000-0003-1644-8603)
- Paula Rodríguez‐Otero (ORCID: https://orcid.org/0000-0001-5236-7785)
- Aurore Perrot (ORCID: https://orcid.org/0000-0003-0131-8689)
- Weili Sun
- Kihyun Kım (ORCID: https://orcid.org/0000-0002-5878-8895)
- Mehmet Turgut (ORCID: https://orcid.org/0000-0002-1036-0232)
- Robin Carson
- Lisa O’Rourke
- Anne Seifert
- Chang Ki Min
- Satoshi Yoshihara
- Vânia Hungria
- Deborah Briseno-Toomey
Institutions
- Royal Marsden NHS Foundation Trust (GB)
- Johnson & Johnson (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Emory University (US)
- University of Calgary (CA)
- Palo Alto University (US)
- Korea University (KR)
- National and Kapodistrian University of Athens (GR)
- Peking University (CN)
- Ondokuz Mayıs University (TR)
- Sichuan University (CN)
- Sahlgrenska University Hospital (SE)
- Odense University Hospital (DK)
- Samsung Medical Center (KR)
- Princess Margaret Cancer Centre (CA)
- Rigshospitalet (DK)
- Centre Hospitalier Universitaire de Toulouse (FR)
- University of Alabama at Birmingham (US)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Sunderby sjukhus (SE)
- West China Hospital of Sichuan University (CN)
- Institute of Cancer Research (CA)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Piedmont Cancer Institute (US)
- St. Antonius Ziekenhuis (NL)
- Hôpital de Jolimont (BE)
- São Germano Oncologia (BR)
- Istituto di Ematologia di Bologna (IT)
- Azienda USL di Bologna (IT)
- Peking University People's Hospital (CN)
- Blackpool Teaching Hospitals NHS Foundation Trust (GB)
- Instituto de Biomedicina de Sevilla (ES)
- Instituto de Investigación Biomédica de Salamanca (ES)
- Clinica Universidad de Navarra (ES)
- Johnson & Johnson (Israel) (IL)
- Centro de Investigación del Cáncer (ES)
- Johnson & Johnson (United Kingdom) (GB)
- Isala (NL)
- Hospital Privado (AR)
- Hospital Universitario Virgen del Rocío (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Klinik und Poliklinik für Psychotherapie und Psychosomatik (DE)
- Gdańsk Medical University (PL)
- University of Tübingen (DE)
- Hyogo University (JP)
- Sungkyunkwan University (KR)
- University of Bologna (IT)
- Stanford University (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-12-09
- DOI
- https://doi.org/10.1056/nejmoa2514663
- Citations
- 9
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 15.93